OrganiGram (OGI) Q3 2025 earnings summary

Executive summary

• Achieved record gross revenue of $110.2M (+73% YoY, +7.2% sequential) and net revenue of $70.8M (+72% YoY, +7.9% sequential) in Q3 FY2025, maintaining leadership in the Canadian cannabis market and expanding internationally.

• International revenue reached $7.4M (+208% YoY, +21% sequential), driven by exports to Germany, Australia, the U.K., and U.S. beverage entry.

• Maintained #1 national market share in Canada for vapes, pre-rolls, milled flower, and hash/concentrates; #3 in edibles and dried flower.

• Overcame temporary ERP integration challenges, regaining and expanding market share by July.

• Completed Motif Labs and Collective Project acquisitions, accelerating beverage category entry and U.S. market presence.

Financial highlights

• Adjusted EBITDA was $5.7M (+64% YoY, +16% sequential); free cash flow reached $5.0M, reversing a negative $4.8M prior year.

• Adjusted gross margin was $24.2M (34% of net revenue), down from 36% in Q3 FY24; standalone margin excluding Motif was 37%.

• Net loss of $6.3M, compared to net income of $2.8M in the prior year, mainly due to non-cash changes in derivative liabilities.

• Total cash position of $85.9M, including $35.9M unrestricted cash and strong liquidity.

• Working capital of $170.5M and shareholders' equity of $385.5M as of June 30, 2025.

Outlook and guidance

• Forecasting adjusted gross margin to average 35% for fiscal 2025, with expectations to approach 40% in the second half of fiscal 2026.

• Anticipates positive free cash flow in Q4 and throughout fiscal 2026.

• EU-GMP certification expected to further boost international sales and margins; larger international flower volumes shipping in Q4 and beyond.

• Continued U.S. expansion with DTC beverage sales in 25 states and new SKUs.

• Ongoing focus on cost synergies, innovation, and leveraging strategic investments for global growth.